6-氯嘌呤核苷结构式
|
常用名 | 6-氯嘌呤核苷 | 英文名 | 6-Chloropurineriboside |
|---|---|---|---|---|
| CAS号 | 5399-87-1 | 分子量 | 286.67 | |
| 密度 | 2.0±0.1 g/cm3 | 沸点 | 614.8±65.0 °C at 760 mmHg | |
| 分子式 | C10H11ClN4O4 | 熔点 | 161-163ºC (dec.) | |
| MSDS | 美版 | 闪点 | 325.6±34.3 °C |
6-氯嘌呤核苷用途氯嘌呤核苷是嘌呤核苷类似物。嘌呤核苷类似物具有广泛的抗肿瘤活性,靶向惰性淋巴系统恶性肿瘤。这一过程中的抗癌机制依赖于抑制DNA合成、诱导细胞凋亡等[1]。 |
| 中文名 | 6-氯嘌呤核苷 |
|---|---|
| 英文名 | 6-Chloropurine riboside |
| 中文别名 | 6-氯嘌呤苷 | 6-氯嘌呤-9-β-D-呋喃核糖苷 |
| 英文别名 | 更多 |
| 描述 | 氯嘌呤核苷是嘌呤核苷类似物。嘌呤核苷类似物具有广泛的抗肿瘤活性,靶向惰性淋巴系统恶性肿瘤。这一过程中的抗癌机制依赖于抑制DNA合成、诱导细胞凋亡等[1]。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 密度 | 2.0±0.1 g/cm3 |
|---|---|
| 沸点 | 614.8±65.0 °C at 760 mmHg |
| 熔点 | 161-163ºC (dec.) |
| 分子式 | C10H11ClN4O4 |
| 分子量 | 286.67 |
| 闪点 | 325.6±34.3 °C |
| 精确质量 | 286.046875 |
| PSA | 113.52000 |
| LogP | -0.56 |
| 外观性状 | 无色结晶粉末 |
| 蒸汽压 | 0.0±1.9 mmHg at 25°C |
| 折射率 | 1.846 |
| 储存条件 | 2-8°C |
| 海关编码 | 2934999090 |
|---|---|
| 中文概述 | 2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途 |
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Evidence on the existence of a purine ligand induced conformational change in the active site of bovine pancreatic ribonuclease A studied by proton nuclear magnetic resonance spectroscopy.
Biochemistry 21(18) , 4290-7, (1982) The titration curves of the C-2 histidine protons of RNase A and of derivative II--a covalent derivative obtained by reaction of the enzyme with the halogenated nucleotide 9-beta-D-ribofuranosyl-6-chl... |
|
|
Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents.
Biochem. Pharmacol. 73 , 1558-1572, (2007) Toxoplasma gondii is an opportunistic pathogen responsible for toxoplasmosis. T. gondii is a purine auxotroph incapable of de novo purine biosynthesis and depends on salvage pathways for its purine re... |
|
|
Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.
Bioorg. Med. Chem. Lett. 17 , 2470-3, (2007) Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-... |
| 6-Chloronebularine |
| 6-CHLOROINOSINE |
| 9H-Purine, 6-chloro-9-β-D-ribofuranosyl- |
| 6-Chloropurine riboside |
| 6-Chloropurine ribos |
| (2R,3R,4S,5R)-2-(6-Chloro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydro-3,4-furandiol |
| 6-Choropurine Riboside |
| 6-Chloropurineriboside |
| 6-Chloropurine-9-Beta-D-ribofuranoside |
| EINECS 217-904-8 |
| (2R,3R,4S,5R)-2-(6-Chloro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| 2',3',5'-tri-O-acetyl-6-chloro adenosine |
| 6-Chlorpurinribosid |
| 9H-purine, 6-chloro-9-(β-d-ribofuranosyl)- |
| 6-CLPR |
| 6-Chloro-9-(β-D-ribofuranosyl)-9H-purine |
| 6-Chloro-9-(β-D-ribofuranosyl)purine |
| MFCD00005738 |
| 6-Chloro-6-deoxyinosine |
| 6-CHLOROPURINE NUCLEOSIDE |
| 6-Chlrorpurine riboside |
| 6-Cl-riboside |
| 6-deamino-6-chloroadenosine |
| 6-Chloro-9-b-D-ribofuranosyl-9H-purine |
| 6-Chloropurine-9-β-D-ribofuranoside |
| 6-chloro-9-pentofuranosylpurine |
| 6-Chloropurinosine |
| 6-Chloropurine ribose |
| 6-Chlor-9-ss-D-ribofuranosylpurin |